CCL4 and type 2 diabetes mellitus: Taken together, these results suggest that while reducing local inflammation and protecting pancreatic β cells via increased insulin expression in a type 1 DM animal model, inhibition of CCL4 with a specific antibody could also attenuate systemic inflammation, improve insulin resistance, and reduce circulating insulin levels in both type 2 diabetes animal models and metabolic syndrome animal models.